Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 468

1.

Fingolimod: a review of its use in the management of relapsing-remitting multiple sclerosis.

Scott LJ.

CNS Drugs. 2011 Aug;25(8):673-98. doi: 10.2165/11207350-000000000-00000. Review.

PMID:
21790210
2.

Oral fingolimod for the treatment of relapsing-remitting multiple sclerosis.

Vasiliou S.

Drugs Today (Barc). 2010 May;46(5):315-25. doi: 10.1358/dot.2010.46.5.1497556. Review.

PMID:
20517533
3.

Fingolimod for relapsing multiple sclerosis: an update.

Horga A, Castilló J, Montalban X.

Expert Opin Pharmacother. 2010 May;11(7):1183-96. doi: 10.1517/14656561003769866. Review.

PMID:
20367536
4.

Oral fingolimod for the treatment of patients with relapsing forms of multiple sclerosis.

Singer B, Ross AP, Tobias K.

Int J Clin Pract. 2011 Aug;65(8):887-95. doi: 10.1111/j.1742-1241.2011.02721.x. Epub 2011 Jun 16. Review.

PMID:
21679286
5.

Teriflunomide for multiple sclerosis.

He D, Zhang C, Zhao X, Zhang Y, Dai Q, Li Y, Chu L.

Cochrane Database Syst Rev. 2016 Mar 22;3:CD009882. doi: 10.1002/14651858.CD009882.pub3. Review.

PMID:
27003123
6.

Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis.

Chun J, Hartung HP.

Clin Neuropharmacol. 2010 Mar-Apr;33(2):91-101. doi: 10.1097/WNF.0b013e3181cbf825. Review.

7.

Oral disease-modifying therapies for relapsing-remitting multiple sclerosis.

Thomas RH, Wakefield RA.

Am J Health Syst Pharm. 2015 Jan 1;72(1):25-38. doi: 10.2146/ajhp140023. Review.

PMID:
25511835
8.

Fingolimod: a review of its use in relapsing-remitting multiple sclerosis.

Sanford M.

Drugs. 2014 Aug;74(12):1411-33. doi: 10.1007/s40265-014-0264-y. Review.

PMID:
25063048
9.

Fingolimod for the treatment of relapsing multiple sclerosis.

Jeffery DR, Markowitz CE, Reder AT, Weinstock-Guttman B, Tobias K.

Expert Rev Neurother. 2011 Feb;11(2):165-83. doi: 10.1586/ern.10.193. Epub 2010 Dec 16. Review.

PMID:
21158700
10.

Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial.

Calabresi PA, Radue EW, Goodin D, Jeffery D, Rammohan KW, Reder AT, Vollmer T, Agius MA, Kappos L, Stites T, Li B, Cappiello L, von Rosenstiel P, Lublin FD.

Lancet Neurol. 2014 Jun;13(6):545-56. doi: 10.1016/S1474-4422(14)70049-3. Epub 2014 Mar 28. Erratum in: Lancet Neurol. 2013 Jun;13(6):536.

PMID:
24685276
11.

A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis.

Kappos L, Radue EW, O'Connor P, Polman C, Hohlfeld R, Calabresi P, Selmaj K, Agoropoulou C, Leyk M, Zhang-Auberson L, Burtin P; FREEDOMS Study Group.

N Engl J Med. 2010 Feb 4;362(5):387-401. doi: 10.1056/NEJMoa0909494. Epub 2010 Jan 20.

12.

Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis.

Cohen JA, Barkhof F, Comi G, Hartung HP, Khatri BO, Montalban X, Pelletier J, Capra R, Gallo P, Izquierdo G, Tiel-Wilck K, de Vera A, Jin J, Stites T, Wu S, Aradhye S, Kappos L; TRANSFORMS Study Group.

N Engl J Med. 2010 Feb 4;362(5):402-15. doi: 10.1056/NEJMoa0907839. Epub 2010 Jan 20.

13.

Fingolimod for relapsing-remitting multiple sclerosis.

La Mantia L, Tramacere I, Firwana B, Pacchetti I, Palumbo R, Filippini G.

Cochrane Database Syst Rev. 2016 Apr 19;4:CD009371. doi: 10.1002/14651858.CD009371.pub2. Review.

PMID:
27091121
14.

Fingolimod: direct CNS effects of sphingosine 1-phosphate (S1P) receptor modulation and implications in multiple sclerosis therapy.

Groves A, Kihara Y, Chun J.

J Neurol Sci. 2013 May 15;328(1-2):9-18. doi: 10.1016/j.jns.2013.02.011. Epub 2013 Mar 19. Review.

15.

Fingolimod is a potential novel therapy for multiple sclerosis.

Aktas O, Küry P, Kieseier B, Hartung HP.

Nat Rev Neurol. 2010 Jul;6(7):373-82. doi: 10.1038/nrneurol.2010.76. Epub 2010 Jun 15. Review.

PMID:
20551946
16.

Long-term effects of fingolimod in multiple sclerosis: the randomized FREEDOMS extension trial.

Kappos L, O'Connor P, Radue EW, Polman C, Hohlfeld R, Selmaj K, Ritter S, Schlosshauer R, von Rosenstiel P, Zhang-Auberson L, Francis G.

Neurology. 2015 Apr 14;84(15):1582-91. doi: 10.1212/WNL.0000000000001462. Epub 2015 Mar 20.

17.

Relapse and disability outcomes in patients with multiple sclerosis treated with fingolimod: subgroup analyses of the double-blind, randomised, placebo-controlled FREEDOMS study.

Devonshire V, Havrdova E, Radue EW, O'Connor P, Zhang-Auberson L, Agoropoulou C, Häring DA, Francis G, Kappos L; FREEDOMS study group.

Lancet Neurol. 2012 May;11(5):420-8. doi: 10.1016/S1474-4422(12)70056-X. Epub 2012 Apr 10. Erratum in: Lancet Neurol. 2012 Aug;11(8):658.

PMID:
22494956
18.

Pharmacokinetic evaluation of fingolimod for the treatment of multiple sclerosis.

Tanasescu R, Constantinescu CS.

Expert Opin Drug Metab Toxicol. 2014 Apr;10(4):621-30. doi: 10.1517/17425255.2014.894019. Epub 2014 Mar 1. Review.

PMID:
24579791
19.

Real-world use of fingolimod in patients with relapsing remitting multiple sclerosis: a retrospective study using the national multiple sclerosis registry in Kuwait.

Al-Hashel J, Ahmed SF, Behbehani R, Alroughani R.

CNS Drugs. 2014 Sep;28(9):817-24. doi: 10.1007/s40263-014-0185-z.

PMID:
25011422
20.

Fingolimod in the treatment algorithm of relapsing remitting multiple sclerosis: a statement of the Central and East European (CEE) MS Expert Group.

Fazekas F, Berger T, Fabjan TH, Ledinek AH, Jakab G, Komoly S, Kraus J, Kurča E, Kyriakides T, Lisý L, Milanov I, Panayiotou P, Jazbec SS, Taláb R, Traykov L, Turčáni P, Vass K, Vella N, Havrdová E.

Wien Med Wochenschr. 2012 Aug;162(15-16):354-66. Epub 2012 Aug 16. Review. Erratum in: Wien Med Wochenschr. 2013 May;163(9-10):251. Multiple author names added.

Supplemental Content

Support Center